HomeCompareNNMX vs KMB

NNMX vs KMB: Dividend Comparison 2026

NNMX yields 1000000.00% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNMX wins by $4.7683925249533696e+36M in total portfolio value
10 years
NNMX
NNMX
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NNMX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — NNMX vs KMB

📍 NNMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNNMXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NNMX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NNMX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNMX
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, NNMX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNMX + KMB for your $10,000?

NNMX: 50%KMB: 50%
100% KMB50/50100% NNMX
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

NNMX
No analyst data
Altman Z
-202.4
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNMX buys
0
KMB buys
0
No recent congressional trades found for NNMX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNNMXKMB
Forward yield1000000.00%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$4.7683925249533696e+36M$45.9K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$5,222.34
Total dividends collected$4.7683311610149396e+36M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NNMX vs KMB ($10,000, DRIP)

YearNNMX PortfolioNNMX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,314$614.45+$100.00MNNMX
2$934,786,450,701$934,679,439,252.34$12,867$760.19+$934786.44MNNMX
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,713$945.27+$8165787108.56MNNMX
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,924$1,181.90+$66665884190957.63MNNMX
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$19,596$1,486.64+$508662171058048128.00MNNMX
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$22,850$1,882.16+$3.62723524842849e+21MNNMX
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$26,849$2,399.80+$2.417368115915061e+25MNNMX
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$31,812$3,083.36+$1.5056740286145463e+29MNNMX
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$38,033$3,994.72+$8.764771002818475e+32MNNMX
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$45,918$5,222.34+$4.7683925249533696e+36MNNMX

NNMX vs KMB: Complete Analysis 2026

NNMXStock

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.

Full NNMX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this NNMX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNMX vs SCHDNNMX vs JEPINNMX vs ONNMX vs KONNMX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.